Perhaps the most interesting clinical-phase candidate in its pipeline right now is CTX001, a gene therapy designed to treat two rare blood disorders -- ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fool.com/investing/2021/05/22/is-vertex-pharmaceuticals-a-buy/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHkIHons46GvAfeskLuBZEUf5j3Tg
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.